CASI Pharmaceuticals Files May 2025 6-K Report
Ticker: CASIF · Form: 6-K · Filed: May 12, 2025 · CIK: 1962738
Sentiment: neutral
Topics: sec-filing, 6-k, press-release
TL;DR
CASI Pharma dropped a May 6-K with a press release - check for news.
AI Summary
CASI Pharmaceuticals, Inc. filed a Form 6-K on May 12, 2025, reporting for the month of May 2025. The filing includes a press release dated May 12, 2025, as Exhibit 99.1. The company's principal executive office is located in Beijing, People's Republic of China.
Why It Matters
This filing provides an update on CASI Pharmaceuticals' activities and regulatory disclosures for May 2025, including a press release that may contain important business developments.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily contains a press release and does not appear to disclose significant new financial or operational risks.
Key Players & Entities
- CASI Pharmaceuticals, Inc. (company) — Filer of the 6-K report
- May 12, 2025 (date) — Date of the press release and filing
- Beijing, People's Republic of China (location) — Location of the company's principal executive office
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report information that CASI Pharmaceuticals, Inc. has made or is required to make public in its home country or has filed or will file with the SEC, specifically including a press release dated May 12, 2025.
What exhibit is included with this 6-K filing?
Exhibit 99.1, a Press Release of CASI Pharmaceuticals, Inc. dated May 12, 2025, is included with this 6-K filing.
Where are CASI Pharmaceuticals, Inc.'s principal executive offices located?
CASI Pharmaceuticals, Inc.'s principal executive offices are located at 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing, 100025, People's Republic of China.
What is the SEC file number for CASI Pharmaceuticals, Inc.?
The SEC file number for CASI Pharmaceuticals, Inc. is 001-41666.
Does CASI Pharmaceuticals, Inc. file annual reports under Form 20-F or Form 40-F?
CASI Pharmaceuticals, Inc. indicates that it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 12, 2025 regarding CASI Pharmaceuticals, Inc. (CASIF).